|
HSPA9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.72320000000937E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.40680000000082E-05 |
| Normal-vs-Stage2 |
4.374000E-02 |
| Normal-vs-Stage3 |
1.57779999954144E-07 |
| Normal-vs-Stage4 |
1.67611999999373E-05 |
| Stage1-vs-Stage2 |
6.998400E-04 |
| Stage1-vs-Stage3 |
1.256600E-01 |
| Stage1-vs-Stage4 |
1.805220E-01 |
| Stage2-vs-Stage3 |
1.164190E-04 |
| Stage2-vs-Stage4 |
1.416520E-04 |
| Stage3-vs-Stage4 |
9.685400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.54140000050174E-08 |
| Normal-vs-AfricanAmerican |
6.09109999999413E-05 |
| Normal-vs-Asian |
3.038400E-04 |
| Caucasian-vs-AfricanAmerican |
6.574200E-01 |
| Caucasian-vs-Asian |
8.079600E-01 |
| AfricanAmerican-vs-Asian |
8.911800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.576500E-04 |
| Normal-vs-Female |
5.626600E-04 |
| Male-vs-Female |
3.622400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.34919999999583E-05 |
| Normal-vs-Age(41-60Yrs) |
1.775000E-04 |
| Normal-vs-Age(61-80Yrs) |
4.051200E-01 |
| Normal-vs-Age(81-100Yrs) |
1.378390E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.271800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.547800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.422400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.951500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.239200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.838400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.821710E-03 |
| Classical-VS-Follicular |
2.981100E-04 |
| Classical-VS-Other |
1.371190E-01 |
| Classical-VS-Normal |
2.82509999949276E-07 |
| Tall-VS-Follicular |
9.22849999973607E-07 |
| Tall-VS-Other |
4.067400E-01 |
| Tall-VS-Normal |
4.78190043118332E-10 |
| Follicular-VS-Other |
5.69750000000147E-05 |
| Follicular-VS-Normal |
1.787630E-01 |
| Other-VS-Normal |
2.02139999999629E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.139900E-02 |
| Normal-vs-N1 |
5.31010000415222E-08 |
| N0-vs-N1 |
5.448200E-04 |
|
|
